This Microarray Technology Launches Advanced Solution For Cannabis Testing Compliance

PathogenDx has introduced QuantX Bacterial, a novel four-in-one assay streamlining microbial testing compliance for cannabis laboratories across states. Headquartered in Scottsdale, Arizona, PathogenDx is a leader in next-generation microarray technology for better health and safety. 

According to a press release, this cutting-edge assay simplifies workflow, optimizes compliance reporting, and accelerates results delivery, eliminating the need for incubation, all from a unified platform.

In addition, PathogenDx enhances its cannabis testing suite by offering manual or automated sample prep options, alongside QuantX Bacterial, Detectx Combined, and QuantX Fungal.

About QuantX Bacterial 

QuantX Bacterial revolutionizes bacterial analysis, encompassing Total Aerobic Bacteria, Bile-tolerant gram-negative bacteria, Enterobacteriaceae, and Total Coliforms within a single array, eliminating the need for separate tests.

The assay delivers semi-quantification of four bacterial indicators and species-specific detection within each category. Its hierarchical PCR design identifies Genus, Species, Family, and Kingdom targets, each test well featuring an Internal Positive Control (IPC) for quantification of PCR amplification, ensuring adaptability for diverse scenarios.

PathogenDx's co-founder and CEO Milan Patel stated, "QuantX Bacterial delivers unrivaled quantitative analysis ease for labs, delivering results within a single shift of sample intake and improving the ROI for clients."

Developed on the foundation of Dynamic Dimensional Detection (D3 Array), a patented multiplexed molecular testing technology, QuantX Bacterial introduces a new benchmark in multiplexing, performance, throughput, and cost-effectiveness. D3 Array, characterized by an open, lattice-like architecture housing up to 108 probes in triplicate within a single well, empowers swift and precise amplicon-target interaction, ensuring high sensitivity and specificity.

Patel further emphasized the platform's efficiency, noting, "In states that require both detections of pathogen species and quantitation, Quantx Bacterial, Detectx Combined, and Quantx Fungal can be run in tandem of a single sample prep and single analytical platform – one equipment set, one standardized workflow, and one reporting system, as opposed to two or three."

To delve deeper into the cannabis testing ecosystem and its standards consider joining us at the 17th edition of the Benzinga Cannabis Capital Conference, which is returning to Chicago on Sept 27-28. Get your tickets today before prices increase and secure a spot at the epicenter of cannabis investment and branding.

Photo: Courtesy Of Louis Reed On Unsplash